In part two of the step-by-step scientific workflow for drug discovery series, Dr Raminderpal Singh and Nina Truter describe the functions of the workflow previously outlined and include key considerations.How GPCR agonists, including antibodies, are shaping the future of metabolic care 9 January ...
hydrophobic-interaction and size-exclusion chromatography (Fig.2a). Notably, the activity eluted from a Superdex 200 size-exclusion column as a single peak at approximately 17 kDa (Fig.2b). Together, our data suggest that the MIWI-potentiating activity corresponds to a...
Claudin 18.2 can potentially be targeted using a wide range of therapeutic modalities beyond monoclonal antibodies including bispecific antibodies, antibody–drug conjugates, chimeric antigen receptor T cells and mRNA-based approaches. The development of claudin 18.2-targeted therapies is expanding and will...
Yang Xin Tang (YXT) is a traditional Chinese herbal preparation which has been reported to improve cognitive function and memory in patients with dementia. As the underlying mechanism of action of YXT has not been elucidated, we examined the effects of YXT and its major herbal components in reg...
Development, production and purification of a pSn-specific recombinant antibody, rec41D3. (A) Vector map of p41D3 (B) Non-reducing Western blot analysis of hybridoma supernatant of mAb 41D3 compared to p41D3-transfected HEK293T cell supernatant using polyclonal antibodies specific for mouse imm...
KSRP associates with AUF1p45 and hnRNPA1 in cytoplasmic extracts of aT3-1 cells. (A) S100 extracts from αT3-1 cells were subjected to gel filtration chromatography on a Superose 6 column. Aliquots of the eluted fractions were analyzed by Western blotting using the indicated antibodies. (B) ...
A Mammalian Target of Rapamycin Inhibitor (mTOR) is a protein kinase that regulates cell growth, proliferation, and differentiation by blocking cell proliferation and disrupting the binding of growth factors to their receptors, thus playing a role in cancer treatment and immunosuppression. ...
In this context, an interesting emerging class of therapeutics are antibodies bound to a cytotoxic agent, known as antibody–drug conjugates (ADCs). ADC targets do not have to be drivers of tumour growth to be meaningful because they serve as an entry point for the cytotoxic agent. This ...
To achieve this, after each round of immunolabeling, the antibodies were eluted from the sections, and they were reimmunolabeled with a different set of antibodies and re-imaged. The tryptophan hydroxylase labeling was included in each round of immunolabeling and then used as a reference for ...
specificity and versatility, we develop a next generation transgenic RNAi system. With this system, the leaky expression of the basal promoter is significantly reduced, as well as the heterozygous ratio of transgenic RNAi flies. In addition, it has been first achieved to precisely and efficiently ...